Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.

Science advances - 1 Jan 2020

Shin Seung-Min, Kim Ji-Sun, Park Seong-Wook, Jun Sei-Yong, Kweon Hye-Jin, Choi Dong-Ki, Lee Dakeun, Cho Yong Beom, Kim Yong-Sung

Abstract excerpt

Oncogenic RAS mutant (RASMUT) proteins have been considered undruggable via conventional antibody regimens owing to the intracellular location restricting conventional-antibody accessibility. Here, we report a pan-RAS-targeting IgG antibody, inRas37, which directly targets the intracellularly activated form of various RASMUT subtypes after tumor cell-specific internalization into the cytosol to block the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endocytosis

Share to Endosomes

Share to Immunoglobulin G

Share to Integrin alphaVbeta3

Share to ras Proteins

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31998840
DOI: 10.1126/sciadv.aay2174
PMCID: PMC6962039

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.PMID 31998840Read ↗

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.Semantic proximity Read ↗

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerSemantic proximity Read ↗

Targeting oncogenic Ras.Semantic proximity Read ↗

Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteinsSemantic proximity Read ↗

Targeting RAS-mutant cancer cells using a synthetic RAS-activated cancer killing system.Semantic proximity Read ↗

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.Semantic proximity Read ↗

A Broad-Based Characterization of a Cell-Penetrating, Single Domain Camelid Bi-Specific Antibody Monomer That Targets STAT3 and KRAS Dependent Cancers.Semantic proximity Read ↗

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.Semantic proximity Read ↗

Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.Semantic proximity Read ↗

Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RASSemantic proximity Read ↗

Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.Semantic proximity Read ↗

Toward targeting the untargetable: A non-canonical EGFR-peptide-drug conjugate achieves potent antitumor activity in KRAS-mutant CRC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.